compound semaglutide and alcohol A clinical trial from the

Spacing drinks out helps, mostly because the timing is less predictable

Phase 2 data also showed retatrutide reducing liver fat more than would be expected from weight loss alone

It would be great to undertake studies with the newer dual agonists and polyagonists also in rare obesity syndromes such as AS, Prader-Willi syndrome, and Bardet-Biedl syndrome (just to name a few) as the clinical need for effective obesity/hyperphagia therapies in these patients is especially high, says Scherer

This first-of-its-kind analysis is a step toward understanding how peer support fits into the bipolar disorder treatment landscape